Tonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYA

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares are trading higher Monday after the company secured a second commercial payer agreement for TONMYA, its recently launched fibromyalgia treatment.

• Tonix stock is among today’s top performers. Why is TNXP stock up today?

Expanding Coverage

The agreement, effective June 1, 2026, was reached with a second leading group purchasing organization (GPO) and provides coverage for TONMYA to an additional approximately 17 million U.S. commercial lives — roughly 10% of the 177 million total commercial lives in the U.S.

Combined with a first GPO agreement announced May 6, total commercial coverage for TONMYA now stands at approximately 52 million U.S. lives, or 29% of total commercial lives in the country.

“TONMYA’s coverage by two leading GPOs is an important milestone in expanding patient access in the early phase of our commercial launch,” said Seth Lederman, M.D., President and CEO of Tonix Pharmaceuticals.

TONMYA, approved by the FDA on August 15, is the first new prescription medicine approved for fibromyalgia in more than 15 years. The drug is also now available under Medicaid in most states, representing approximately 75 million lives, with Medicare discussions continuing to advance.

Fibromyalgia affects more than 10 million adults in the U.S.

Tonix Shares Advance

TNXP Price Action: At the time of publication, Tonix shares are trading 6.14% higher at $11.75, according to data from Benzinga Pro.

This illustration was generated using artificial intelligence via Midjourney.